Status:
UNKNOWN
Clinical Trial Through Combined tACS Therapy in Patients With Mild Cognitive Impairment
Lead Sponsor:
Universidad del Desarrollo
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
The aging of the population has led to an increase in the prevalence of disabling and high-cost diseases, such as dementia and Mild Cognitive Impairment (MCI). The latter can be considered a prodromal...
Detailed Description
Background At the global level, sociodemographic change is happening, characterized by progressive aging of the population and a modification of the epidemiological profile, with an increase in the pr...
Eligibility Criteria
Inclusion
- Age equal to or greater than 60 years.
- Presence of Mild Cognitive Impairment, according to the diagnostic criteria established in Petersen et al. (2014).
- Have six or more years of complete schooling (presence of reading and writing).
Exclusion
- The previous diagnosis of other neurodegenerative diseases.
- Attending another cognitive training program.
- History of Epilepsy or current presence of epileptic seizures.
- Presence of psychiatric diseases.
- Presence of a relevant depressive picture (GDS \>=2).
- History of important neurological alterations such as the history of stroke, transient ischemic attack, cranial brain trauma.
- Important alterations of communication.
Key Trial Info
Start Date :
January 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 21 2024
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT05291208
Start Date
January 26 2022
End Date
September 21 2024
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Investigación del Desarrollo de Cognición y Lenguaje, Faculty of Medicine, Universidad de Valparaíso.
Valparaíso, Región de Valparaíso, Chile, 2520000